BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 35920706)

  • 1. Hepatic Adenoma Subtypes on Hepatobiliary Phase of Gadoxetic Acid-Enhanced MRI: Systematic Review and Meta-Analysis.
    Kim TH; Woo S; Ebrahimzadeh S; McInnes MDF; Gerst SR; Do RK
    AJR Am J Roentgenol; 2023 Jan; 220(1):28-38. PubMed ID: 35920706
    [No Abstract]   [Full Text] [Related]  

  • 2. Value of Texture Analysis on Gadoxetic Acid-Enhanced MRI for Differentiating Hepatocellular Adenoma From Focal Nodular Hyperplasia.
    Cannella R; Rangaswamy B; Minervini MI; Borhani AA; Tsung A; Furlan A
    AJR Am J Roentgenol; 2019 Mar; 212(3):538-546. PubMed ID: 30557050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HBP-enhancing hepatocellular adenomas and how to discriminate them from FNH in Gd-EOB MRI.
    Auer TA; Walter-Rittel T; Geisel D; Schöning W; Schmelzle M; Müller T; Sinn B; Denecke T; Hamm B; Fehrenbach U
    BMC Med Imaging; 2021 Feb; 21(1):28. PubMed ID: 33588783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic Value of Gadoxetic Acid-Enhanced MR Imaging to Distinguish HCA and Its Subtype from FNH: A Systematic Review.
    Guo Y; Li W; Cai W; Zhang Y; Fang Y; Hong G
    Int J Med Sci; 2017; 14(7):668-674. PubMed ID: 28824299
    [No Abstract]   [Full Text] [Related]  

  • 5. Focal Nodular Hyperplasia and Hepatocellular Adenoma: Accuracy of Gadoxetic Acid-enhanced MR Imaging--A Systematic Review.
    McInnes MD; Hibbert RM; Inácio JR; Schieda N
    Radiology; 2015 Nov; 277(2):413-23. PubMed ID: 26020440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative correlation between uptake of Gd-BOPTA on hepatobiliary phase and tumor molecular features in patients with benign hepatocellular lesions.
    Reizine E; Amaddeo G; Pigneur F; Baranes L; Legou F; Mulé S; Zegai B; Roche V; Laurent A; Rahmouni A; Calderaro J; Luciani A
    Eur Radiol; 2018 Oct; 28(10):4243-4253. PubMed ID: 29721686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic value of morphological enhancement patterns in the hepatobiliary phase of gadoxetic acid-enhanced MRI to distinguish focal nodular hyperplasia from hepatocellular adenoma.
    Bilreiro C; Soler JC; Ayuso JR; Caseiro-Alves F; Ayuso C
    Radiol Med; 2021 Nov; 126(11):1379-1387. PubMed ID: 34287759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differentiating focal nodular hyperplasia from hepatocellular adenoma: Is hepatobiliary phase MRI (HBP-MRI) using linear gadolinium chelates always useful?
    Roux M; Pigneur F; Baranes L; Calderaro J; Chiaradia M; Decaens T; Kastahian S; Charles-Nelson A; Tselikas L; Costentin C; Laurent A; Azoulay D; Mallat A; Rahmouni A; Luciani A
    Abdom Radiol (NY); 2018 Jul; 43(7):1670-1681. PubMed ID: 29110059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The diagnostic value of Gd-EOB-DTPA-MRI for the diagnosis of focal nodular hyperplasia: a systematic review and meta-analysis.
    Suh CH; Kim KW; Kim GY; Shin YM; Kim PN; Park SH
    Eur Radiol; 2015 Apr; 25(4):950-60. PubMed ID: 25537979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intrapatient Comparison of the Hepatobiliary Phase of Gd-BOPTA and Gd-EOB-DTPA in the Differentiation of Hepatocellular Adenoma From Focal Nodular Hyperplasia.
    Vanhooymissen IJSML; Thomeer MG; Braun LMM; Gest B; van Koeverden S; Willemssen FE; Hunink M; De Man RA; Ijzermans JN; Dwarkasing RS
    J Magn Reson Imaging; 2019 Mar; 49(3):700-710. PubMed ID: 30252977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. OATPB1/B3 and MRP3 expression in hepatocellular adenoma predicts Gd-EOB-DTPA uptake and correlates with risk of malignancy.
    Sciarra A; Schmidt S; Pellegrinelli A; Maggioni M; Dondossola D; Pasquier J; Cigala C; Tosi D; Halkic N; Bulfamante G; Viale G; Bosari S; Balabaud C; Bioulac-Sage P; Sempoux C
    Liver Int; 2019 Jan; 39(1):158-167. PubMed ID: 30218633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iso- or hyperintensity of hepatocellular adenomas on hepatobiliary phase does not always correspond to hepatospecific contrast-agent uptake: importance for tumor subtyping.
    Reizine E; Ronot M; Pigneur F; Purcell Y; Mulé S; Dioguardi Burgio M; Calderaro J; Amaddeo G; Laurent A; Vilgrain V; Luciani A
    Eur Radiol; 2019 Jul; 29(7):3791-3801. PubMed ID: 30937584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inflammatory hepatocellular adenomas can mimic focal nodular hyperplasia on gadoxetic acid-enhanced MRI.
    Agarwal S; Fuentes-Orrego JM; Arnason T; Misdraji J; Jhaveri KS; Harisinghani M; Hahn PF
    AJR Am J Roentgenol; 2014 Oct; 203(4):W408-14. PubMed ID: 25055198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatospecific MR contrast agent uptake on hepatobiliary phase can be used as a biomarker of marked β-catenin activation in hepatocellular adenoma.
    Reizine E; Ronot M; Ghosn M; Calderaro J; Frulio N; Bioulac-Sage P; Trillaud H; Vilgrain V; Paradis V; Luciani A
    Eur Radiol; 2021 May; 31(5):3417-3426. PubMed ID: 33146794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value of discrepancy of the central scar-like structure between dynamic CT and gadoxetate disodium-enhanced MRI in differentiation of focal nodular hyperplasia and hepatocellular adenoma.
    Park HJ; Byun JH; Kang JH; Kang HJ; Yu E; Lee SJ; Kim SY; Won HJ; Shin YM; Kim PN
    Eur J Radiol; 2021 Jun; 139():109730. PubMed ID: 33930719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MRI for characterization of benign hepatocellular tumors on hepatobiliary phase: the added value of in-phase imaging and lesion-to-liver visual signal intensity ratio.
    Lebert P; Adens-Fauquembergue M; Azahaf M; Gnemmi V; Behal H; Luciani A; Ernst O
    Eur Radiol; 2019 Nov; 29(11):5742-5751. PubMed ID: 30993437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta-Catenin-Mutated Hepatocellular Adenomas at Hepatobiliary Phase MRI: A Systematic Review and Meta-Analysis.
    Shen L; Altmayer S; Tse JR
    J Magn Reson Imaging; 2024 Feb; ():. PubMed ID: 38465878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differentiation of focal nodular hyperplasia and hepatocellular adenoma using qualitative and quantitative imaging features and classification and regression tree analysis.
    Alamri TM; Cerny M; Al Shaikh M; Billiard JS; Olivié D; Chagnon M; Tang A
    Abdom Radiol (NY); 2023 Mar; 48(3):874-885. PubMed ID: 36528729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatocellular Adenoma Subtypes Based on 2017 Classification System: Exploratory Study of Gadoxetate Disodium-Enhanced MRI Features With Proposal of a Diagnostic Algorithm.
    Tse JR; Felker ER; Cao JJ; Naini BV; Liang T; Lu DSK; Raman SS
    AJR Am J Roentgenol; 2023 Apr; 220(4):539-550. PubMed ID: 36169546
    [No Abstract]   [Full Text] [Related]  

  • 20. Differentiation of focal nodular hyperplasia from hepatocellular adenoma: Role of the quantitative analysis of gadobenate dimeglumine-enhanced hepatobiliary phase MRI.
    Roux M; Pigneur F; Calderaro J; Baranes L; Chiaradia M; Tselikas L; Decaens T; Costentin C; Laurent A; Azoulay D; Mallat A; Zafrani ES; Rahmouni A; Luciani A
    J Magn Reson Imaging; 2015 Nov; 42(5):1249-58. PubMed ID: 25851028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.